文献速递其他结缔组织病

阿巴西普治疗肌炎相关间质性肺病

Abatacept for the treatment of myositis-associated interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项随机、安慰剂对照的先导试验评估阿巴西普在抗合成酶综合征相关间质性肺病(ASyS-ILD)患者中的疗效与安全性。第24周时两组%FVC变化无显著差异(组间差异-0.35,95%CI -6.91至6.21,P=0.914),但第48周观察到有利于阿巴西普的趋势且无统计学显著性;阿巴西普总体耐受良好。

要点

  • 第24周%FVC变化阿巴西普组与安慰剂组无显著差异(组间差异-0.35,95%CI -6.91至6.21,P=0.914)。
  • 第48周%FVC、FVC(ml)、%DLCO及SOBQ呈有利于阿巴西普的趋势但无统计学显著性。
  • 阿巴西普组肺病活动度VAS及%FVC与QIA评分的基线前后斜率显著改善,总体耐受良好。

核心结论

  • 阿巴西普未显著改善第24周%FVC,但第48周趋势提示潜在获益,支持需要更大规模长期随机对照试验。

研究设计与样本

  • 随机、安慰剂对照先导试验,活动性ASyS-ILD患者随机接受阿巴西普(n=9)或安慰剂(n=11)24周,随后全部接受阿巴西普开放标签延长24周。
  • 主要终点为基线至第24周%预计用力肺活量(%FVC)变化,研究未针对主要或次要终点进行效能计算。

主要发现

  • 第24周主要终点%FVC变化阿巴西普组与安慰剂组无显著差异,组间差异-0.35(95%CI -6.91至6.21,P=0.914),所有次要终点亦无显著差异。
  • 第48周观察到%FVC、FVC(ml)、%DLCO及SOBQ有利于阿巴西普的趋势,但无统计学显著性。
  • 阿巴西普组肺病活动度VAS及%FVC与QIA评分的基线前后斜率显著改善。
  • 阿巴西普总体耐受良好。

关键数值与推荐

  • 第24周%FVC变化组间差异-0.35(95%CI -6.91至6.21,P=0.914)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究未针对主要或次要终点进行效能计算。
  • 第48周%FVC、FVC(ml)、%DLCO及SOBQ的有利于阿巴西普的趋势无统计学显著性。
  • 结论指出支持需要更大规模长期随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD). METHODS: Participants with active ASyS-ILD were randomized to receive abatacept (n = 9) or placebo (n = 11) for 24 weeks, followed by a 24-week open-label extension with abatacept for all participants. The primary endpoint was a change in % predicted forced vital capacity (%FVC) from baseline to week 24. Secondary endpoints included changes in the FVC (ml), % predicted diffusing capacity of the lung for carbon monoxide (%DLCO), shortness of breath questionnaire (SOBQ) and pulmonary disease activity on a visual analogue scale (VAS) at weeks 24 and 48. Pre-post baseline analysis of FVC and quantitative image analysis (QIA) of high-resolution computed tomographic scans were performed. Data were analysed using a generalized linear mixed model. The study was not powered for primary or secondary endpoints. RESULTS: At week 24, there was no significant difference in the primary endpoint of %FVC change between abatacept and placebo (between treatment difference of -0.35, 95%CI -6.91 to 6.21, P = 0.914) and in all secondary endpoints. However, by week 48, trends favouring abatacept in %FVC, FVC (ml), %DLCO and SOBQ were observed without statistical significance. There was a significant improvement in pulmonary disease activity VAS and pre-post baseline slopes of %FVC and QIA scores in the abatacept arm. Abatacept was generally well tolerated. CONCLUSION: Abatacept did not significantly improve %FVC at 24 weeks. However, trends at 48 weeks suggest potential benefits, supporting the need for a larger, long-term randomized controlled trial. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov; NCT03215927.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Pongtarakulpanit N, Sullivan DI, et al. Abatacept for the treatment of myositis-associated interstitial lung disease. Rheumatology (Oxford). 2025. PMID: 40272902. doi:10.1093/rheumatology/keaf218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。